Oral sucrosomial iron versus intravenous iron in anemic cancer patients without iron deficiency receiving darbepoetin alfa: a pilot study
| Autor: | A. Prestifilippo, Rocco Giannicola, D. Azzarello, Antonino Mafodda, Dario Giuffrida, Roberto Maisano, M. Mare |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Male
medicine.medical_specialty Oral iron Darbepoetin alfa Anemia Iron medicine.medical_treatment Administration Oral Pilot Projects 030204 cardiovascular system & hematology Sucrosomial iron Gastroenterology 03 medical and health sciences 0302 clinical medicine hemic and lymphatic diseases Neoplasms Internal medicine medicine Humans Hematinic IV iron Chemotherapy-related anemia Retrospective Studies chemistry.chemical_classification Chemotherapy business.industry Iron deficiency medicine.disease Surgery Oncology Tolerability chemistry Hb response Transferrin 030220 oncology & carcinogenesis Injections Intravenous Hematinics Quality of Life Female Original Article Hemoglobin business medicine.drug |
| Zdroj: | Supportive Care in Cancer |
| ISSN: | 1433-7339 0941-4355 |
| DOI: | 10.1007/s00520-017-3690-z |
| Popis: | Purpose Erythropoiesis-stimulating agents (ESAs) are often used in treatment of patients with chemotherapy-induced anemia. Many studies have demonstrated an improved hemoglobin (Hb) response when ESA is combined with intravenous iron supplementation and a higher effectiveness of intravenous iron over traditional oral iron formulations. A new formulation of oral sucrosomial iron featuring an increased bioavailability compared to traditional oral formulations has recently become available and could provide a valid alternative to those by intravenous (IV) route. Our study evaluated the performance of sucrosomial iron versus intravenous iron in increasing hemoglobin in anemic cancer patients receiving chemotherapy and darbepoetin alfa, as well as safety, need of transfusion, and quality of life (QoL). Materials and methods The present study considered a cohort of 64 patients with chemotherapy-related anemia (Hb >8 g/dL |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink